ArticleOral radiology2021
Magnetic resonance image biomarkers improve differentiation of benign and malignant parotid tumors through diagnostic model analysis.
Article in Oral radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Radiomics-Based Diagnosis in Dentomaxillofacial Radiology: A Systematic Review.Journal of imaging informatics in medicine · 2025Pooled it
- Machine learning-based radiomics for histological classification of parotid tumors using morphological MRI: a comparative study.European radiology · 2022Trial
- Radiographic biomarkers on grayscale gradient transition zone improve differentiation of deep caries/reversible pulpitis and chronic pulpitis through diagnostic model analysis.Oral radiology · 2025Article
- Performance of radiomics in the differential diagnosis of parotid tumors: a systematic review.Frontiers in oncology · 2024Review
- Radiomics Analysis in Characterization of Salivary Gland Tumors on MRI: A Systematic Review.Cancers · 2023Review
- The Role of an MRI-Based Radiomic Signature in Predicting Malignancy of Parotid Gland Tumors.Cancers · 2023Article
- Computed tomography-based texture assessment for the differentiation of benign, borderline, and early-stage malignant ovarian neoplasms.The Journal of international medical research · 2023Article
- The Role of Radiomics in Salivary Gland Imaging: A Systematic Review and Radiomics Quality Assessment.Diagnostics (Basel, Switzerland) · 2022Review
- Article
- Artificial Intelligence-based Radiomics in the Era of Immuno-oncology.The oncologist · 2022Review
- Apparent Diffusion Coefficient Map-Based Radiomics Features for Differential Diagnosis of Pleomorphic Adenomas and Warthin Tumors From Malignant Tumors.Frontiers in oncology · 2022Article
- Histogram analysis of dynamic contrast-enhanced magnetic resonance imaging in the differential diagnosis of parotid tumors.BMC medical imaging · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo explore the effectiveness of magnetic resonance image (MRI)-based biomarkers for identifying benign and malignant parotid tumors via diagnostic model analysis.
methodsThis retrospective study included 109 patients (development cohort and validation cohort) who underwent MRI preoperatively, including T1- and T2-weighted images. Parameters based on 2D or 3D texture analysis were extracted from tumor lesions by MaZda software, fisher discriminant and bootstrap method were used to perform parameter reduction, diagnostic models with the selected biomarkers were established along with clinical data, model performance (discrimination and calibration) was furtherly evaluated by internal and external validation, decision curve analysis was applied to measure the improvement of clinical benefits.
resultsS(5,5) Entrop, S(0,1) ASM, WavEnHH (s-4), S(1,1,0) Entropy and Perc.10% were significantly associated with the pathological diagnosis of parotid tumor (benign versus malignancy), when adding these biomarkers to the regression analysis, model performance significantly improved in the development cohort (likelihood-ratio-test; p < 0.05, with an increase of AUC from 0.72 (reference model) to 0.85), and these results were maintained in a small external validation cohort. Decision curve analysis indicated that clinical benefit was greater with the application of MRI-based biomarkers.
conclusionsMRI-based texture analysis is proven to be an effective tool in differentiating benign and malignant parotid tumors, preoperative diagnosis was improved with the selected biomarkers compared to the reference model.
Indexed as
Identifiers
33428106What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.